Neutralization of HIV-1 by antibody

Current Opinion in Immunology

Volumn 8, Issue 4, 1996, Pages 540-545

  Sattentau, Quentin J ^a  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY SPECIFICITY; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION CONTROL; NONHUMAN; REVIEW; SEROCONVERSION; TREATMENT FAILURE; VACCINE PRODUCTION;

EID: 0030219572     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80044-6     Document Type: Article

References (51)

1. Dimmock NJ. Update on the neutralization of animal viruses. Rev Med Virol. 5:1995;165-179.
2. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, Hendry RM. Investigators: Neutralization of primary isolates by anti-envelope monoclonal antibodies. AIDS. 9:1995;867-874.
3. Moore JP, Ho DD. HIV neutralization: the consequence of viral adaptation to growth on transformed T cells. (suppl A) AIDS. 9:1995;S117-S136.
4. Poignard P, Klasse PJ, Sattentau QJ. Neutralization of the human immunodeficiency virus type 1. Immunol Today. 17:1996;239-246.
5. Nathan R. gp120: good, bad or indifferent? Nat Med. 1:1995;1105-1106.
6. Fust G, Dierich MP, Hidvegi T. Role of humoral factors in the progression of HIV disease. Immunol Today. 16:1995;167-169.
7. Moore JP. Back to primary school. Nature. 376:1995;115-116.
8. Golding H, D'Souza MP, Bradac J, Mathieson B, Fast P. Neutralization of HIV-1. Aids Res Hum Retroviruses. 10:1994;633-643.
9. Sawyer LS, Wrin MT, Crawford-Miksza L, Potts B, Wu Y, Weber PA, Alfonso RD, Hanson CV. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol. 68:1994;1342-1349.
10. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH. Adaptation to persistent growth in the H9 cell line renders a primary isolate of Human Immunodeficiency Virus Type 1 sensitive to neutralization by vaccine sera. J Virol. 69:1995;39-48.
11. Moore JP, Cao Y, Qing L, Sattenlau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton DR, Ho DD. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol. 69:1995;101-109.
12. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 67:1993;6642-6647.
13. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, Burton D. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1994;1024-1027.
14. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF III, Burton D, Ho DD, Moore JP. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 69:1995;6609-6617.
15. Klasse JP, Moore JP. A quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T cell line adapted strains of the human immunodeficiency virus type 1. of special interest J Virol. 70:1996;3668-3677 Theoretical model presenting a unified theory explaining the relative resistance of primary isolates compared with TCLA isolates.
16. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line passaged human immunodeficiency virus type 1 isolates. of special interest J Virol. 69:1995;4413-4422 This paper shows that poor neutralization of HIV-1 viruses carrying primary isolate gp120 can be correlated with weak mAb binding. Antibody- and soluble CD4-mediated enhancement of virus infection is also demonstrated.
17. Gaudin M-C, Allaway GP, Maddon PJ, Barbas CF III, Burton DR, Koup RA. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. of special interest J Virol. 70:1996;2586-2592 The neutralization profile of plasma virus was different from that of primary viruses isolated from the same plasma into peripheral blood leukocytes; this illustrates the concept of `to culture is to change'.
18. Gu Z, Li X, Quan Y, Parniak MA, Wainberg MA. Studies of a neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and non-nucleoside inhibitors, respectively. J Virol. 70:1996;2620-2626.
19. Arthur LO, Bess JW Jr, Sowder RC, Benveniste RE, Mann DL, Chermann JC, Henderson LE. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science. 258:1992;1935-1938.
20. Conley AJ, Gorny MK, Kessler JA, Boots LI, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, Zolla-Pazner S. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol. 68:1994;6994-7000.
21. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore J, Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. of special interest J Virol. 70:1996;1100-1108 Characterization of a new human mAb to a unique, conserved epitope on gp120 that potently neutralizes primary isolates.
22. Bukawa H, Sekigawa K, Hamajima K, Fukushima J, Yamada Y, Kiyono H, Okuda K. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. of special interest Nat Med. 1:1995;681-685 Convincing demonstration that a novel vaccine formulation can induce a neutralizing IgA response at the mucous membrane.
23. Guo MMM, Hildreth JEK. HIV acquires functional adhesion receptors from host cells. in press AIDS Res Hum Retroviruses. 1996.
24. Saifuddin M, Ghassemi M, Patki C, Parker CJ, Spear GT. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retroviruses. 10:1994;829-837.
25. Chan WL, Rodgers A, Grief C, Almond N, Ellis S, Flanagan B, Silvera P, Bootman J, Stott J, Kent K, Bomford R. Immunization with class-I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. of special interest Aids. 9:1995;223-228 Demonstration that a xenogeneic response to human HLA class I antigens can protect macaques from challenge by SIV grown in human cells.
26. Arthur LO, Bess JW, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE. Macaques immunized with HLA-DR are protected from challenge with Simian Immunodeficiency Virus. of special interest J Virol. 69:1995;3117-3124 This paper demonstrates that a xenogeneic response to human HLA class II antigens can protect macaques from challenge by SIV grown in human cells.
27. Gomez MB, Hildreth JEK. Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. J Virol. 69:1995;4628-4632.
28. Sattentau OJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. of special interest J Exp Med. 182:1995;185-196 Neutralizing mAb binding to oligomeric, virion-associated gp120 correlates broadly with neutralization, but mAb binding to monomeric gp120 does not, implying that oligomeric gp120 is a more relevant immunogen than the monomeric glycoprotein. Moreover, mAB affinity is shown to be a major determinant of HIV neutralization.
29. Stamatatos L, Cheng-Mayer C. Structural modulations of the envelope gp120 glycoprotein human immunodeficiency virus type 1 upon oligomerization and differential V3 loop-epitope exposure of isolates displaying distinct tropism upon virion- soluble receptor binding. J Virol. 69:1995;6191-6198.
30. Richardson TMJ, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW. Humoral response to oligomeric human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 70:1996;753-762.
31. VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. of special interest J Immunol. 155:1995;4100-4110 Sera from vaccinees immunized with soluble gp120 bind well to soluble gp120 but poorly to virus-associated gp120 which may partially explain poor results obtained with recent vaccine trials.
32. Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, Moss B. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol. 68:1994;3015-3026.
33. Broder CC, Earl PL, Long D, Abedon ST, Moss B, Doms R. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA. 91:1994;11699-11703.
34. Schonning K, Jansson B, Olofsson S, Nielsen JO, Hansen J-ES. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology. 218:1996;134-140.
35. McDougal JS, Kennedy MS, Orloff SL, Nicholson JKA, Spira TJ. Mechanisms of HIV-1 neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. in press J Virol. 70:1996.
36. VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield RR, Birx DL. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol. 153:1994;449-459.
37. Moore JP, Nara PL. The role of the V3 loop of gp120 in HIV infection. AIDS. 5:1991;S21-S33.
38. 1. in press J Virol. 1996.
39. Poignard P, Fouts T, Naniche D, Moore JP, Sattentau QJ. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. of special interest J Exp Med. 183:1996;473-484 The first demonstration that certain neutralizing mAbs can induce gp120 dissociation from gp41 in a manner similar to soluble CD4 inactivation of TCLA viruses.
40. Moore JP, McKeating JA, Norton WA, Sattentau QJ. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virons: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralisation by soluble CD4. J Virol. 65:1991;1133-1140.
41. Schutten M, Andeweg AC, Bosch ML, Osterhaus AD. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. of special interest Scand J Immunol. 41:1995;18-22 Convincing evidence for Fc receptor independent enhancement of HIV-1 infection by mAb and soluble CD4; a mAb which was neutralizing for one primary isolate env species was enhancing for another.
42. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol. 70:1996;445-458.
43. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol. 68:1994;5142-5155.
44. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 68:1994;6103-6110.
45. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 68:1994;4650-4655.
46. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. of special interest N Engl J Med. 332:1995;201-208 This paper documents significantly higher levels of neutralizing activity in the sera of long-term survivors in sera from progressors, although the interpretation of these data is difficult.
47. McKnight A, Clapham PR. Immune escape and tropism of HIV. Trends Microbiol. 3:1995;356-361.
48. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, Fenyo EM. Mother to child transmission of human immunodeficiency virus type 1: correction with neutralizing antibodies against primary isolates. J Infect Dis. 168:1993;207-210.
49. Parren PWHI, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF III, Burton DR, Mosier DE. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. of special interest AIDS. 9:1995;F1-F6 Evidence from the human peripheral blood leukocyte hu-PBL-SCID mouse model that a potently neutralizing mAb can protect mice from challenge with a TCLA virus. Can this be repeated with primary isolates?
50. Back NK, Smit L, De Jong JJ, Keulen W, Schutten M, Goudsmit J, Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology. 199:1994;431-438.
51. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol. 69:1995;5723-5733.